Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + etoposide–cisplatin in first-line small cell ovarian carcinoma of hypercalcemic type
2024-515310-40-01Phase 2Authorised
- Sponsor
- Arcagy-Gineco
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), sponsored by Arcagy-Gineco. Primary endpoint: Complete response rate. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)
Beyond the preview
Go deeper on 2024-515310-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515310-40-01.